Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. — Investor Relations & Filings

Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 179530

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 92% confidence The document is labeled “분기보고서” covering the period from 2026-01-01 to 2026-03-31. It contains detailed company overview, financial data tables (e.g., capital changes, sales breakdown), business descriptions, and other substantive quarterly reporting sections typical of a comprehensive interim financial report. It is clearly the full quarterly report itself rather than an announcement or presentation. Therefore, it is classified as an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
파생상품거래손실발생
Regulatory Filings Classification · 95% confidence The document is a short Korean regulatory disclosure announcing a loss on derivative transactions (conversion bonds’ fair value losses) with details on amounts, causes, and date. It does not contain full financial statements, nor is it a standalone report like an annual or interim report. It is a compliance announcement under regulatory filing requirements. Hence, it best fits the catch-all 'Regulatory Filings' category.
2026-05-15 Korean
[기재정정]주주총회소집결의 (임시주주총회)
Proxy Solicitation & Information Statement Classification · 82% confidence The document is a formal notice of convening a shareholders’ meeting (an Extraordinary General Meeting) with details on date, time, venue, record date, board resolution date, and agenda items. It is designed to inform shareholders and solicit their attendance/votes rather than reporting financials or announcing voting results. This aligns with the Proxy Solicitation & Information Statement category.
2026-05-14 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 85% confidence The document is a Korean ‘주요사항보고서’ (material event report) concerning a decision on a 유상증자 (paid-in capital increase) by third‐party allotment, including details on subscription payment dates, listing dates, and amendment of the original disclosure. This is a direct announcement of a new share issue/capital change rather than an annual report or earnings release. Therefore, it falls under Share Issue/Capital Change (SHA).
2026-05-14 Korean
[기재정정]주요사항보고서(자기전환사채매도결정)
Capital/Financing Update Classification · 85% confidence The document is a Korean “주요사항보고서” which discloses a corporate financing event – the decision to sell self-convertible bonds – and here provides a correction to that disclosure. It is neither an annual/quarterly report nor an earnings or governance filing, but rather an update on a capital structure/financing transaction. This falls squarely under “Capital/Financing Update” (CAP).
2026-05-12 Korean
주주총회소집결의 (임시주주총회)
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice convening an extraordinary shareholders’ meeting (“임시주주총회”) with date, time, venue, record date, board resolution date, and agenda items. It is providing shareholders with meeting information and requesting participation/votes, which corresponds to proxy solicitation/information materials for a shareholder meeting. Therefore, it falls under Proxy Solicitation & Information Statement (PSI).
2026-04-20 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.